Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688091's PB Ratio is ranked worse than 83.53% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs SHSE:688091: 5.18
During the past 12 months, Shanghai Yizhong Pharmaceutical Co's average Book Value Per Share Growth Rate was 1.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 25.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Shanghai Yizhong Pharmaceutical Co was 65.20% per year. The lowest was 2.60% per year. And the median was 31.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Shanghai Yizhong Pharmaceutical Co PB Ratio Related Terms
Shanghai Yizhong Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Yizhong Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Yizhong Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Yizhong Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Yizhong Pharmaceutical Co's PB Ratio falls into.
Shanghai Yizhong Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) has a PB Ratio of 5.18 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors. This is 25% below median its historical median of 6.87. Over the past decade, Shanghai Yizhong Pharmaceutical Co's PB Ratio has ranged from 2.94 to 16.56. According to the industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #771 out of 923 companies in the Drug Manufacturers industry, placing it in the top 83.5%.
Is Shanghai Yizhong Pharmaceutical Co's PB Ratio too high?
Shanghai Yizhong Pharmaceutical Co's current PB Ratio of 5.18 is 25% below median its 10-year median of 6.87. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 16.56. The Drug Manufacturers industry median PB Ratio is 1.88. Shanghai Yizhong Pharmaceutical Co's value of 5.18 is 175.5% above this industry median. Based on the distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #771 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Yizhong Pharmaceutical Co has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Yizhong Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #771 out of 923 companies for PB Ratio. This places Shanghai Yizhong Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.88. Shanghai Yizhong Pharmaceutical Co's value of 5.18 is 175.5% above this benchmark. Historically, Shanghai Yizhong Pharmaceutical Co's own PB Ratio has ranged from 2.94 to 16.56 over the past decade. While the company's 10-year median is 6.87 vs. the industry median of 1.88, Shanghai Yizhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Yizhong Pharmaceutical Co's current PB Ratio of 5.18 is 175.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Shanghai Yizhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Yizhong Pharmaceutical Co's current PB Ratio is 5.18, which is 25% below median its own 10-year median of 6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Yizhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co (SHSE:688091) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥50.45, compared to a current price of ¥36.31 — trading 28% below its estimated fair value. The current PB Ratio is 5.18, which is 25% below median its 10-year median of 6.87 and 175.5% above the Drug Manufacturers industry median of 1.88. Shanghai Yizhong Pharmaceutical Co's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Shanghai Yizhong Pharmaceutical Co (SHSE:688091), the current PB Ratio is 5.18 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥36.31 is trading 28% below its estimated GF Value™ of ¥50.45.
GuruFocus considers Shanghai Yizhong Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688091:
PB Ratio: 5.18 (25% below median its 10-year median of 6.87)
GF Value™: ¥50.45 vs. price of ¥36.31 (28% below fair value)
Industry Position: 175.5% above the Drug Manufacturers median (#771 of 923)
No single metric tells the full story. See the SHSE:688091 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
52GF Score
Get the complete analysis for SHSE:688091
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688091 has been successfully added to your 
